The companies Vaxcyte, Generate Biomedicines, and Immunic bagged the biggest biotech funding rounds overall in February 2026.

As Demy-Colton and EBD Group’s Biotech Showcase™ concluded its 18th year SAN FRANCISCO, CA, UNITED STATES, February 10, ...

February 2026 saw a major biopharma acquisition, four key buyouts, and licensing deals in antibodies, small molecules, and ...

The biotechnology market is entering a new growth phase, driven by the convergence of genomic science, artificial intelligence, and precision medicine, as global R&D investment approaches $360 billion ...

Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announced ...

Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied about 35% over the past six months (as of Nov. 20, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 12%). Year to ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

Issued on behalf of Oncolytics Biotech Inc. Oncolytics Biotech Inc. (TSX: ONC) has officially entered the most critical phase of its development journey—pursuing a potential registration-enabling ...

The market seems to be falling heavily out of love with the AI stocks, and for good reason: CapEx is rising at a staggering ...

Raleigh-based Slate Medicines just pulled in a hefty $130 million Series A, a war chest the startup says will fuel ...

Biotech stocks are emerging from a four-year slump. The SPDR S&P Biotech exchange-traded fund XBI, a proxy for the sector, is up 25% so far this year through Oct. 31, beating the S&P 500 SPX by 9 ...

Picture a world where most life-saving medicines are discovered not in the United States, but in Beijing and Shanghai. Imagine a time when the most advanced biotechnologies, therapies that cure cancer ...